This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Endo (ENDP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are expected to focus on the Xiaflex performance and pipeline updates when Endo (ENDP) reports third-quarter results.
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Epizyme (EPZM) incurs narrower-than-expected loss in the third quarter of 2018. The company is on track to submit an NDA for tazemetostat in epithelioid sarcoma in the first half of 2019.
ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss in Q3. However, it misses estimates for revenues. Shares down.
Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3
by Zacks Equity Research
Shire (SHPG) misses earnings and revenue estimates in the third quarter of 2018. The company completes the sale of its Oncology franchise in the quarter.
AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues
by Zacks Equity Research
AMAG reports wider than expected loss in the third quarter of 2018. The company completed the sale of Cord Blood Registry in August 2018.
The Zacks Analyst Blog Highlights: Amazon, Facebook, Mastercard and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Facebook, Mastercard and Merck
Dow Recovers More Than 900 Points in 3 Days: 5 Top Picks
by Nalak Das
The meltdown of the 30-stock Dow was transitory in nature and can provide a good entry point for investors.
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
by Zacks Equity Research
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports in line earnings in the third quarter of 2018 and announces restructuring plans.
Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the third quarter of 2018. The company also updates its 2018 outlook.
Top Analyst Reports for Amazon, Facebook, Mastercard & Merck
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Amazon (AMZN), Facebook (FB), Mastercard (MA) and Merck (MRK).
Clovis (CLVS) Q3 Earnings & Sales Lag, Rubraca Disappoints
by Zacks Equity Research
Clovis (CLVS) misses estimates in the third quarter for both earnings and sales and guides lower sales for only marketed drug, Rubraca in Q4. Shares decline.
Sanofi's (SNY) Q3 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Sanofi (SNY) beats on earnings as well as sales in the third quarter of 2018. Sales benefit from the performance of Specialty care segment and recovery in Vaccine segment.
The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead
by Kinjel Shah
Pipeline success, cost cutting, share buybacks, product launches, increased M&A and collaboration activities are the factors that drives the large-cap pharma industry.
Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View
by Zacks Equity Research
Incyte (INCY) third-quarter earnings and revenues miss estimates but rise year over year.
What's in Store for Verastem (VSTM) This Earnings Season?
by Zacks Equity Research
On Verastem's (VSTM) third-quarter conference call, investor focus will be on the company's launch and reimbursement plans for its newly approved leukemia drug Copiktra.
Pfizer (PFE) Beats on Q3 Earnings, Meets Sales, Narrows View
by Zacks Equity Research
Pfizer's (PFE) third-quarter earnings beat estimates while sales match the same. The company narrows its full-year sales and profit targets
Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Allergan (AGN) beats third-quarter estimates for earnings and sales and raises its full-year guidance for both the metrics. Botox remains the primary sales driver.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $71.45, moving +1.49% from the previous trading session.
Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark
by Zacks Equity Research
Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.
Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO
by Zacks Equity Research
Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.
Company News For Oct 26, 2018
by Zacks Equity Research
Companies In The News Are: CMCSA,TWTR,COP,MRK
Dow 30 Stock Roundup: Boeing, Caterpillar, Intel, Microsoft Earnings Impress
by Swarup Gupta
The index suffered declines on most days of the week, weighed down by multiple concerns.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q3 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.
Merck (MRK) Beats on Q3 Earnings, Lags Sales, Ups EPS View
by Zacks Equity Research
Merck (MRK) beat estimates for earnings while missing the same for sales in third-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.